Zegfrovy global licensing deal supports AstraZeneca stock at GBX11,866 support

Traders Union
All News
Financial News
AstraZeneca slides 0.32% to GBX12,324

Highlights

AstraZeneca secured a global licensing deal with Dizal Pharmaceutical for Zegfrovy, generating a $600 million upfront payment and exposure to a new oncology asset.
Ongoing clinical pipeline expansion includes a multicenter MET gene profiling study and early-stage trials in oncology and diabetes, signaling strategic R&D momentum.
AZN/GBX trades under major moving averages amid persistent bearish momentum, with price likely to fluctuate between GBX11,866 and GBX12,781 near term.

Liquidity boost and pipeline growth as flagship licensing deal closes

AstraZeneca finalized a landmark global licensing agreement with China's Dizal Pharmaceutical for Zegfrovy, an EGFR exon 20 inhibitor, entailing a $600 million upfront payment and up to $900 million in milestone payments, according to Pharmaceutical Technology. This inflow provides substantial immediate liquidity and exposure to an approved oncology product, creating potential for incremental revenue across international markets. In parallel, the company has also initiated a multicenter study on MET gene profiling in non-small cell lung cancer, advancing its precision oncology strategy, while further progress on early-stage trials such as AZD7760 in Japan and the Eluminate-2 diabetes study reflect continued expansion of its clinical development pipeline. Collectively, these research and partnership developments may influence medium-term prospects for AZN, though price action has remained under broader selling pressure.

Downtrend momentum as multiple sell signals reinforce technical barriers

On the technical front, AZN is trading below its 20-day moving average at GBX12,606, the 50-day moving average at GBX13,215, and beneath the 200-day moving average at GBX13,801 on the daily chart. The Ichimoku Kijun sits at GBX12,775 and is acting as immediate resistance. Momentum indicators are firmly negative: the Moving Average Convergence Divergence (MACD) and Average Directional Index (ADX) both show sell signals, while the Relative Strength Index (RSI), Commodity Channel Index (CCI), Stochastic RSI, and Bull/Bear Power all indicate oversold conditions with pronounced seller dominance. The Awesome Oscillator also confirms the prevailing downtrend, and the market’s low volatility has kept prices close to today’s upper intraday range.

Limited rebound potential as downside risk dominates trading outlook

Over the next several trading days, AZN is expected to fluctuate between the support at GBX11,866 and resistance at GBX12,781, likely consolidating within this volatility band. The probability of a sustained reversal is low amid prevailing downside pressure; a bearish scenario would be confirmed by a break below GBX11,866, which could speed up declines. Conversely, a recovery attempt would first need to clear the GBX12,775 resistance to signal a potential bounce, but this remains a lower-probability scenario under current technical conditions.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca’s recent licensing deal and pipeline advances as supportive but not enough to reverse current downside momentum. The stock’s technical profile remains weak, with prices below key moving averages and all major indicators in negative territory. He believes the prevailing selling pressure will likely keep AZN range-bound near support, unless a move above GBX12,775 materializes. "As long as AZN trades below GBX12,775, I remain cautious and see no clear reversal signal," the expert says.

Earlier, analysts noted that confidence in AstraZeneca's research pipeline had become more fragile following a major clinical trial setback that weighed heavily on sentiment. While recent licensing deals and early-stage pipeline activity add potential longer-term drivers, sustained negative momentum suggests that a confirmed breakdown below GBX11,866 remains the primary downside risk for investors to monitor.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.